妥卡尼（利多卡因类似物）的人体电药理学

Human Electropharmacology of Tocainide, a lidocaine congener.

作者信息

Horowitz L N, Josephson M E, Farshidi A

出版信息

Am J Cardiol. 1978 Aug;42(2):276-80. doi: 10.1016/0002-9149(78)90910-4.

Abstract

The electropharmacology of tocainide, an orally active congener of lidocaine, was evaluated in 10 patients with coronary artery disease. Electrophysiologic measurements including sinus nodal recovery time, sinoatrial conduction time, intraatrial conduction time, atrial, atrioventricular (A-V) nodal and ventricular refractory periods and intraventricular conduction time were obtained before and after intravenous infusion of tocainide. At blood levels shown to be effective against ventricular arrhythmias, tocainide produced no statistically significant changes in the electrophysiologic measurements, although occasional marked individual effects were observed. No side effects were observed during these studies. No adverse effects on A-V conduction were observed in patients with an intraventricular conduction disturbance or a prolonged control H-V interval. Thus, plasma tocainide concentrations effective in the therapy of ventricular arrhythmias exert no adverse effects on cardiac electrophysiologic properties in patients with coronary artery disease.

摘要

对10例冠心病患者评估了利多卡因的口服活性类似物妥卡尼的电药理学特性。在静脉输注妥卡尼前后，进行了包括窦房结恢复时间、窦房传导时间、心房内传导时间、心房、房室（A-V）结和心室不应期以及心室内传导时间在内的电生理测量。在显示对室性心律失常有效的血药浓度下，妥卡尼在电生理测量中未产生统计学上的显著变化，尽管偶尔观察到明显的个体效应。在这些研究中未观察到副作用。在有室内传导障碍或对照H-V间期延长的患者中，未观察到对房室传导的不利影响。因此，对室性心律失常治疗有效的血浆妥卡尼浓度对冠心病患者的心脏电生理特性无不利影响。